Analysts expect that Akorn, Inc. (NASDAQ:AKRX) will announce earnings per share (EPS) of $0.10 for the current quarter, Zacks reports. Three analysts have provided estimates for Akorn’s earnings, with the highest EPS estimate coming in at $0.15 and the lowest estimate coming in at $0.07. The company is expected to announce its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that Akorn will report full-year earnings of $0.39 per share for the current financial year, with EPS estimates ranging from $0.25 to $0.52. For the next fiscal year, analysts forecast that the firm will report earnings of $0.37 per share, with EPS estimates ranging from $0.20 to $0.60. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover Akorn.
Akorn (NASDAQ:AKRX) last announced its earnings results on Wednesday, August 1st. The company reported ($0.06) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.08 by ($0.14). Akorn had a negative net margin of 24.21% and a negative return on equity of 12.84%. The business had revenue of $190.94 million for the quarter, compared to the consensus estimate of $187.40 million.
Shares of NASDAQ AKRX opened at $6.32 on Friday. Akorn has a fifty-two week low of $5.25 and a fifty-two week high of $33.63. The company has a quick ratio of 2.87, a current ratio of 3.94 and a debt-to-equity ratio of 1.13.
A number of large investors have recently bought and sold shares of the business. BlackRock Inc. grew its position in Akorn by 30.6% in the 2nd quarter. BlackRock Inc. now owns 10,731,745 shares of the company’s stock worth $178,040,000 after purchasing an additional 2,515,409 shares during the period. Marshall Wace LLP boosted its stake in shares of Akorn by 250.5% during the 2nd quarter. Marshall Wace LLP now owns 2,069,385 shares of the company’s stock worth $34,331,000 after acquiring an additional 1,478,959 shares during the last quarter. Paulson & CO. Inc. purchased a new position in shares of Akorn during the 2nd quarter worth $29,198,000. Natixis boosted its stake in shares of Akorn by 31.3% during the 2nd quarter. Natixis now owns 1,500,471 shares of the company’s stock worth $24,893,000 after acquiring an additional 357,981 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Akorn by 75.7% during the 2nd quarter. Northern Trust Corp now owns 1,409,291 shares of the company’s stock worth $23,379,000 after acquiring an additional 607,101 shares during the last quarter. 69.81% of the stock is owned by institutional investors and hedge funds.
Akorn Company Profile
Akorn, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health.
Featured Story: Trading Strategy Examples and Plans
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Akorn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn and related companies with MarketBeat.com's FREE daily email newsletter.